Dean Park
Hematology & Oncology · Bethesda, MDNPI 1205983004
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. 2023 is the largest year on record at $606, more than ten times the $29 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in MD, where the typical reported total is $2,111.
Across 52 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$139
- Bristol Myers Squibb$92
- Incyte Corporation$81
- Karyopharm Therapeutics Inc.$69
- G1 Therapeutics, Inc.$66
- Sanofi$60
- plus $631 from 23 others
What the payments were for
- Food & beverage$1,139100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 7 | $139 |
| Bristol Myers Squibb | 4 | $92 |
| Incyte Corporation | 4 | $81 |
| Karyopharm Therapeutics Inc. | 3 | $69 |
| G1 Therapeutics, Inc. | 3 | $66 |
| Sanofi | 2 | $60 |
| GSK | 2 | $50 |
| Mirati Therapeutics, Inc. | 2 | $49 |
| Morphosys, US Inc. | 2 | $45 |
| Exelixis Inc. | 2 | $44 |
| Amgen | 3 | $44 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Beigene USA, Inc. | 1 | $27 |
| Tersera Therapeutics LLC | 1 | $26 |
| Gilead | 1 | $26 |
| AVEO Pharmaceuticals, Inc. | 1 | $24 |
| Seagen Inc. | 1 | $24 |
| Immunogen, Inc. | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $22 |
| ADC Therapeutics America, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| CTI Biopharma Corp. | 1 | $19 |
| Merck | 1 | $15 |
| Pfizer | 1 | $14 |
How this compares
$1,139 in reported general payments places this provider in the 40th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Bethesda
- Ralph BocciaBethesda$3.1M
- Sandra SwainBethesda$1M
- Chitra RajagopalBethesda$89K
- Susan LeitmanBethesda$44K
- Giuseppe GiacconeBethesda$32K
- Phillip ScheinbergBethesda$27K
- Steven PavleticBethesda$13K
- Kashif AliSilver Spring$987K
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.